Indications |
Oral Overactive bladder Adult: 2.5-5 mg bid-tid. May be increased to max 5 mg 4 times daily if necessary. As extended-release preparation: Initially, 5 mg once daily increased by 5 mg every wk if necessary to max 30 mg daily. Child: >7 yr for nocturnal enuresis: 2.5-3 mg bid increased if necessary to 5 mg bid-tid. Last dose should be given before bedtime. As extended-release preparation: 5 mg once daily, increased by 5 mg wkly if necessary to max 20 mg daily. Elderly: Initially, 2.5-3 mg bid increased to 5 mg bid if necessary. Oral Neurogenic bladder disorders Child: >5 yr: 2.5 or 3 mg bid increased to 5 mg bid according to response. Max 5 mg tid. Transdermal Overactive bladder Adult: 1 transdermal system (delivering 3.9 mg per day) applied to dry, intact skin on the abdomen, hip, or buttock twice wkly. |
Contraindications |
GI obstruction or atrophy, severe toxic megacolon, significant bladder outflow obstruction, glaucoma, urinary retention. |
Warnings / Precautions |
Elderly; hepatic or renal impairment; neuropathy; hyperthyroidism; prostatic hyperplasia; hiatus hernia; cardiac disease, reflux oesophagitis, ulcerative colitis, myasthenia gravis; pregnancy and lactation. High environmental temperature might cause heat prostration (fever with heat stroke due to decreased sweating). |
Adverse Reactions |
Dry mouth, constipation, nausea, abdominal pain; blurred vision; headache, dizziness, drowsiness; dry skin, rash; photosensitivity, diarrhoea, insomnia, palpitation, weakness, dry eyes, confusion, hypertension, UTI, dyspepsia. |
Overdose Reactions |
Anticholinergic effects including CNS excitation (e.g. restlessness, tremor, irritability, convulsions, delirium, hallucinations), flushing, fever, dehydration, cardiac arrhythmia, vomiting, and urinary retention may occur after overdose. Treatment should be symptomatic and supportive. Activated charcoal may be administered. |
Drug Interactions |
Co-administration with other anticholinergic drugs may cause undesirable increased anticholinergic effects. Additive sedation with CNS depressants and alcohol. Concentration may be increased by CYP3A4 inhibitirs (e.g. imidazole antifungals, macrolide antibiotics). See Below for More oxybutynin Drug Interactions |
Mechanism of Actions |
Oxybutynin exerts direct antispasmodic effect on the smooth muscle by inhibiting the muscarinic action of acetylcholine. It exhibits moderate anticholinergic effect, but has potent antispasmodic effects on urinary smooth muscle. Absorption: Peak plasma concentrations after 1 hr. Distribution: Crosses the blood-brain barrier; enters breast milk. Metabolism: Hepatic: Undergoes first-pass metabolism. Excretion: Excreted in urine and faeces as metabolites. Elimination half life 2-3 hr. |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store at 15-30°C (59-86°F). Transdermal: Store at 15-30°C (59-86°F). |
ATC Classification |
G04BD04 - oxybutynin ; Belongs to the class of urinary antispasmodics. |
Storage |
Oral: Store at 15-30°C (59-86°F). Transdermal: Store at 15-30°C (59-86°F). |
Available As |
|
Oxybutynin
Post Review about Oxybutynin Click here to cancel reply.
Oxybutynin Containing Brands
Oxybutynin is used in following diseases
Drug - Drug Interactions of Oxybutynin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.